A Phase 2, Open-Label Study of the Efficacy, Safety, and Tolerability of Dynavax's Immunostimulatory Phosphorothiolate Oligodeoxyribonucleotide, 1018 ISS, Following Rituxan (Rituximab) Treatment in Patients With CD20+, B-Cell Follicular Non-Hodgkin's Lymphoma.
Phase of Trial: Phase II
Latest Information Update: 14 Oct 2017
At a glance
- Drugs 1018-ISS; Rituximab
- Indications Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 02 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 12 May 2009 Additional lead trial centre identified as reported by ClinicalTrials.gov.
- 12 May 2009 Planned end date changed from Dec 2008 to Jul 2009 as reported by ClinicalTrials.gov.